VIMPAT Receives EU Approval for Expanded Pediatric Use
News
The European Commission has approved the expansion of the use of UCB’s VIMPAT (lacosamide) to include monotherapy and adjunctive therapy of partial-onset (focal) seizures in children aged 4 years and older. This approval ... Read more